Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6638769 | 0.92 | ELANE (0.55) | ELANECTRB1KMT2ACYP17A1POLB | |
| SCHEMBL6637543 | 0.91 | CTRB1 (0.53) | ELANECTRB1KMT2APOLBCYP3A4 | |
| SCHEMBL6635955 | 0.88 | ELANE (0.56) | ELANECTRB1KMT2A | |
| SCHEMBL6637344 | 0.85 | ELANE (0.51) | ELANECTRB1CYP17A1 | |
| SCHEMBL6635647 | 0.85 | ELANE (0.60) | ELANECTRB1 | |
| SCHEMBL6717299 | 0.84 | CTRB1 (0.54) | ELANECTRB1KMT2APOLBCYP3A4 | |
| SCHEMBL6638394 | 0.81 | CTRB1 (0.56) | ELANECTRB1CYP17A1RCE1NR1H4 | |
| SCHEMBL6638871 | 0.80 | ELANE (0.61) | ELANECTRB1KMT2ACYP17A1CYP3A4 | |
| SCHEMBL6636762 | 0.79 | ELANE (0.51) | ELANECTRB1CYP3A4 | |
| SCHEMBL6638457 | 0.78 | ELANE (0.49) | ELANECTRB1KMT2ACYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |